Biogen Inc. (BIIB)

188.38 -0.21 (-0.11%) At close: 04:00PM EDT

Biogen Inc.

225 Binney Street
Cambridge, MA 02142
United States
617 679 2000
https://www.biogen.com

Sector(s): Healthcare
Industry: Drug Manufacturers - General
Full-time employees: 7,570

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Christopher A. Viehbacher	President, CEO & Director	4.07M	N/A	1961
Mr. Michael R. McDonnell CPA	Executive VP & CFO	2.21M	N/A	1964
Ms. Nicole Murphy	Head of Pharmaceutical Operations & Technology	1.45M	N/A	1973
Ms. Susan H. Alexander Esq.	Executive VP & Chief Legal Officer	1.95M	N/A	1957
Mr. Rachid Izzar	Head of Global Product Strategy & Commercialization	1.27M	N/A	1975
Ms. Robin C. Kramer	Senior VP & Chief Accounting Officer	N/A	N/A	1966
Mr. Charles E. Triano	Senior VP & Head of Investor Relations	N/A	N/A	N/A
Ms. Natacha Gassenbach	Chief Communication Officer & Head of Corporate Affairs	N/A	N/A	N/A
Mr. Adam Keeney Ph.D.	Executive VP & Head of Corporate Development	N/A	N/A	1977
Dr. Ginger Gregory Ph.D.	Executive VP & Chief Human Resources Officer	1.59M	N/A	1968

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Corporate governance

Biogen Inc.’s ISS governance QualityScore as of 1 October 2024 is 3. The pillar scores are Audit: 8; Board: 2; Shareholder rights: 2; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.